Thursday, April 25, 2013
Publication and contact
Semisynthetic synthesis of artemisinin
Biological production of artemisinic
acid and chemical conversion of the acid to artemisinin could
help supply first-line treatments for malaria infection at low cost.
Artemisinin is naturally produced in the plant Artemisia annua. Saccharomyces
cerevisiae expressing A. annua enzymes synthesized the artemisinin
precursor artemisinic acid, which then was extracted from suspension at more
than 10-fold higher titers than those produced by other methods. A 4-step
chemical synthesis process was used to synthesize artemisinin from
artemisinic acid with an overall yield of 40%-45% and with higher purity than
plant-derived artemisinin. Next steps include commercializing the process to
produce artemisinin-based combination therapies to treat malaria infection.
Novartis AG markets the
artemisinin-based combination therapy Coartem
to treat malaria.
Sigma-Tau Group and Pfizer Inc. market Eurartesim
to treat malaria.
Suda Ltd.'s ArTiMist,
a sublingual aerosol formulation of artemisinin, is in Phase III testing for
Published online April 25, 2013
Patent status undisclosed; Amyris
Inc. exclusively licensed the technology to the Institute
for OneWorld Health, which has licensed it to Sanofi;
available for licensing for non-malaria indications
Paddon, C.J. et al.
Nature; published online April 10, 2013;
Contact: Chris J. Paddon, Amyris Inc., Emeryville, Calif.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]